IBIO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 Apr 2024 @ 16:00):

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States...

Stats
Today's Volume	268 846
Average Volume	3.89M
Market Cap	16.09M
EPS	$0 ( 2024-02-13 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0110 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-01	Brenner Martin	Sell	4 881	Common Stock
2023-10-03	Brenner Martin	Sell	5 267	Common Stock
2023-10-02	Brenner Martin	Sell	4 215	Common Stock
2023-08-28	Brenner Martin	Sell	5 011	Common Stock
2023-08-23	Duran Felipe	Buy	60 000	Stock Option (right to buy)

INSIDER POWER
86.00
Last 90 transactions
Buy: 50 085 445 \| Sell: 29 398 433

Volume Correlation

Long: -0.21 (neutral)

Short: 0.86 (strong)

Signal:(41.62) Same movement expected

Ibio Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ibio Inc Correlation - Currency/Commodity

0.37
( neutral )

0.03
( neutral )

0.00
( neutral )

0.37
( neutral )

Ibio Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.11M (0.00 %)
EPS:	$-47.87

Q4	2023
Revenue:	$0
Gross Profit:	$-31 000.00 (0.00 %)
EPS:	$-5.94

Q3	2023
Revenue:	$0
Gross Profit:	$-282 000 (0.00 %)
EPS:	$-9.58

Q2	2023
Revenue:	$0
Gross Profit:	$-299 000 (0.00 %)
EPS:	$-68.43

Financial Reports:

No articles found.

Ibio Inc

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.